SEC Form 4 · accession 0001209191-17-023841
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Sachdev
Officer — EVP, CRO
Period of report
Mar 29, 2017
Accepted (ET)
Mar 31, 2017 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 29, 2017 | M | 5,719 | $38.80 | A | 105,054 | D | |
| Common Stock | Mar 29, 2017 | M | 17,156 | $37.86 | A | 122,210 | D | |
| Common Stock | Mar 29, 2017 | M | 29,032 | $48.74 | A | 151,242 | D | |
| Common Stock | Mar 29, 2017 | M | 28,593 | $45.11 | A | 179,835 | D | |
| Common Stock | Mar 29, 2017 | S | 51,468 | $106.30 | D | 128,367 | D | |
| Common Stock | Mar 29, 2017 | S | 29,032 | $110.00 | D | 99,335 | D | |
| Common Stock | holding | — | — | — | 882 | I | 401k |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $38.80 | Mar 29, 2017 | M | 5,719 | D | — | Feb 2, 2021 | Common Stock | 5,719 | 0 | D |
| Stock Option (Right to Buy)F2 | $37.86 | Mar 29, 2017 | M | 17,156 | D | — | Feb 1, 2022 | Common Stock | 17,156 | 0 | D |
| Stock Option (Right to Buy)F2 | $48.74 | Mar 29, 2017 | M | 29,032 | D | — | Jul 24, 2022 | Common Stock | 29,032 | 0 | D |
| Stock Option (Right to Buy)F2 | $45.11 | Mar 29, 2017 | M | 28,593 | D | — | Feb 4, 2023 | Common Stock | 28,593 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- F2Fully vested.